A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer

@article{Ho2017ASO,
  title={A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer},
  author={T. Ho and R. N{\'u}{\~n}ez-Nateras and Yue-xian Hou and A. Bryce and D. Northfelt and A. Dueck and B. Wong and M. Stanton and R. Joseph and E. Castle},
  journal={Clinical Genitourinary Cancer},
  year={2017},
  volume={15},
  pages={196–202.e1}
}
Micro‐Abstract A study to evaluate the toxicity of combination bicalutamide and raloxifene was conducted in patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose reductions were required. The patient assessment of quality of life showed no statistically significant changes. The combination of bicalutamide and raloxifene treatment was well tolerated. Background: Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER‐&agr; and ER‐&bgr;, and estrogen‐based… Expand
4 Citations

References

SHOWING 1-10 OF 55 REFERENCES
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
  • 91
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
  • 107
...
1
2
3
4
5
...